Gene therapy has shown great promise in treating a variety of genetic disorders, but the high cost of these treatments has made them inaccessible to many patients. Boro Dropulić, the executive director of Caring Cross, believes that by leveraging technology innovations and forming partnerships with hospitals and governments, gene therapies can be made more affordable and accessible worldwide.
One of the main challenges of gene therapy is the cost, which can run into millions of dollars for a single treatment. This has limited the availability of these life-changing therapies to only a select few who can afford them. Dropulić and his team at Caring Cross are working to change this by finding ways to reduce the cost of gene therapies and increase their accessibility to patients in need.
By partnering with hospitals and governments, Caring Cross is able to negotiate lower prices for gene therapies and secure funding to help cover the cost of treatment for patients. This not only makes these therapies more affordable for individuals, but also ensures that they are accessible to a wider range of patients who can benefit from them.
In addition to forming partnerships, Dropulić is also focused on leveraging technology to streamline the process of delivering gene therapies. By utilizing digital health platforms and telemedicine services, Caring Cross is able to reach patients in remote areas who may not have access to traditional healthcare facilities. This not only expands the reach of gene therapy treatments, but also makes it more convenient for patients to receive the care they need.
Overall, Dropulić is optimistic about the future of gene therapy and believes that by working together with hospitals, governments, and technology partners, we can make these life-saving treatments more affordable and accessible to patients around the world. Through collaboration and innovation, Caring Cross is paving the way for a future where gene therapies are not only effective, but also within reach for all who need them.
